Aptose Announces Reverse Share Split

Core Viewpoint - Aptose Biosciences Inc. has announced a plan to consolidate its outstanding common shares on a 1-for-30 basis to comply with Nasdaq's minimum bid price requirement and to attract a broader range of investors [1][2]. Group 1: Share Consolidation Details - The company currently has 64,301,183 common shares outstanding, which will be reduced to approximately 2,143,372 common shares post-consolidation [2]. - The reverse share split is subject to approval by the Toronto Stock Exchange and is expected to take effect on February 26, 2025 [2]. - No fractional common shares will be issued; any resulting fractions will be canceled without consideration [2]. Group 2: Shareholder Instructions - Registered shareholders will receive a Letter of Transmittal to facilitate the exchange of pre-reverse split common shares for post-reverse split shares [3]. - Shareholders holding shares through brokers will not need to complete a Letter of Transmittal [3]. Group 3: Impact on Securities - The exercise or conversion price and the number of common shares under outstanding warrants, convertible notes, and stock options will be proportionately adjusted to reflect the reverse share split [4]. Group 4: Company Overview - Aptose Biosciences is focused on developing precision medicines for oncology, particularly in hematology, with its lead product being the oral kinase inhibitor tuspetinib (TUS) [5]. - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [5].